Showing results (31-40 of 267) with videos related to
Sort By:
Pageof 27
Transfusion|May 26, 2012
Alterations of platelet function and clot formation kinetics after in vitro exposure to anti-A and -BMajed A Refaai, Jessie Carter, Kelly F Henrichs, et al.Expert Review of Hematology|October 31, 2013
Transfusion immunomodulation from a clinical perspective: an updateMajed A Refaai, Neil BlumbergTransfusion Clinique Et Biologique : Journal De La Societe Francaise De Transfusion Sanguine|September 12, 2022
How do we forecast tomorrow's transfusion? - Next generation transfusion practices to improve recipient safetyNeil Blumberg, Joanna Mary HealBest Practice & Research. Clinical Anaesthesiology|April 18, 2013
The transfusion dilemma--weighing the known and newly proposed risks of blood transfusions against the uncertain benefitsMajed A Refaai, Neil BlumbergFrontiers in Immunology|February 22, 2017
NF-κB Links TLR2 and PAR1 to Soluble Immunomodulator Factor Secretion in Human PlateletsPauline Damien, Fabrice Cognasse, Bernard Payrastre, et al.Clinical Immunology (Orlando, Fla.)|May 4, 2002
Human B lymphocytes and B lymphomas express PPAR-gamma and are killed by PPAR-gamma agonistsJosué Padilla, Edmund Leung, Richard P PhippsLeukemia Research|December 5, 2003
Inhibition of cyclooxygenase-2: a new targeted therapy for B-cell lymphoma?Richard P Phipps, Elizabeth Ryan, Steven H BernsteinEuropean Journal of Immunology|January 29, 2002
Fibroblast subsets in the human orbit: Thy-1+ and Thy-1- subpopulations exhibit distinct phenotypesLaura Koumas, Terry J Smith, Richard P PhippsJournal of Immunology (Baltimore, Md. : 1950)|October 4, 2006
The peroxisome proliferator-activated receptor gamma (PPARgamma) ligands 15-deoxy-Delta12,14-prostaglandin J2 and ciglitazone induce human B lymphocyte and B cell lymphoma apoptosis by PPARgamma-independent mechanismsDenise M Ray, Filiz Akbiyik, Richard P PhippsPageof 27